Sort   by:  
 Page size 
TranscriptomicsThe RALA pathway can maintain the proliferation of KRAS- and BRAF-mutated cancer cells
By silencing of RALA, a downstream member of the RAS signal transduction pathway, we aimed to determine whether genes downstream of a mutated KRAS (codon 12 or 13) or a mutated BRAF can have significant functions in colorectal cancer carcinogenesis. RALA was silenced in three colorectal cancer cell ...
ORGANISM(S): Homo sapiens 
2015-06-20 | E-GEOD-39857 | biostudies-arrayexpress
ProteomicsMolecular dynamics of acquired vemurafenib-resistance in dogs with naturally ocurring BRAF-mutated Urothelial Carcinoma
Dogs treated with Vemurafenib were surveyed for naturally aquired drug resistance using proteomics and phosphoproteomics
ORGANISM(S): Canis familiaris (Dog) (Canis lupus familiaris) 
2026-01-01 | PXD062194 | Pride
Dog Braf-mutated carcinoma Urothelial carcinoma 
UnknownSelection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.
Not available
S-EPMC9296927 | biostudies-literature
UnknownSuccessful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma.
Not available
S-EPMC7476408 | biostudies-literature
UnknownConstruction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
Not available
S-EPMC9215106 | biostudies-literature
TranscriptomicsBRAF-induced tumorigenesis is IKKalpha dependent but NF?B independent
Tumor cells carrying KRAS mutations activate the NF-?B pathway by different mechanisms, which contribute to the acquisition of essential cancer properties. The BRAF kinase, a downstream mediator of KRAS, is also mutated in a subset of colorectal cancers (CRC), which predicts bad prognosis and therap...
ORGANISM(S): Homo sapiens 
2015-05-08 | E-GEOD-57979 | biostudies-arrayexpress
UnknownEfficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
Not available
S-EPMC9300506 | biostudies-literature
GenomicsSuccessful BRAF/MEK-inhibition in a young patient with BRAF V600E-mutated extrapancreatic acinar cell carcinoma (HIPO-021)
Pancreatic acinar cell carcinoma (PAC) is a rare but dismal disease with a peak incidence rate around 60 to 70 years of age. Treatment options in case of metastatic disease are limited and often follow chemotherapeutic regimens for pancreatic ductal adenocarcinoma. Even though recurrent genomic alte...
EGAS00001004282 | EGA
UnknownLong term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.
Not available
S-EPMC10774964 | biostudies-literature
UnknownIdentification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process.
Not available
S-EPMC9577413 | biostudies-literature
Sort   by:  
 Page size